Risvodetinib
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2020 (NCT04350177)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase V-ABLINHIBITOR
ABL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cncc(-c3oncc3C)c2)n1- Mol. weight
- 574.69 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314481 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06644326 | Phase 1 | Jun 21, 2023 | Inhibikase Therapeutics, Inc. |
| NCT06641557 | Phase 1 | Feb 21, 2023 | Inhibikase Therapeutics, Inc. |
| NCT05424276 | Phase 2 | May 23, 2022 | Inhibikase Therapeutics, Inc. |
| NCT04350177 | Phase 1 | Jul 1, 2020 | Celerion, Inhibikase Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Celerion | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1